This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Reinventing Brainlab
Herzlinger, Regina E.; Dessain, Vincent; Misztal, KarolCase HBS-313069-EStrategyThe management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment.Starting at €8.20
-
Cray Research, Inc. (Spanish Version)
Aguilar, Francis J.; Brainard, Caroline E.Case HBS-306S14Knowledge and CommunicationCray Research se enfrenta a varios problemas de gestión, como resultado de un crecimiento rápido y la necesidad de un crecimiento continuo. Temas a tratar incluyen: 1) si Cray debe ser un marketing o una compañía de tecnología; 2) la competencia nueva y poderosa; 3) productos para ofrecer como Cray se mueve fuera de su segmento de mercado inicial; 4) dolores de crecimiento (es decir, la cultura corporativa, comunicaciones, etc.) y 5) ¿hay "vida d...Starting at €8.20
-
Nota de introducción a DAAG Europe
Aguilar, Francis J.; Svensk, Robert E.Case HBS-306S33Knowledge and CommunicationComplementa el caso.Starting at €8.20
-
DAAG Europe (A) (Spanish Version)
Aguilar, Francis J.; Svensk, Robert E.Case HBS-311S01Knowledge and CommunicationEmpresa debe decidir si subir los precios y restringir el crédito del consumidor a la luz de su estrategia para la producción de racionalizar, introducir una nueva línea de ascensores modelo y aumentar su cuota de mercado. Puntos hasta las interrelaciones de las diferentes áreas funcionales dentro de una estrategia corporativa y en cierta medida el período de tiempo asociado con el cambio estratégico.Starting at €8.20
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20
-
General Electric, 1984 (Spanish Version)
Aguilar, Francis J.; Hamermesh, Richard G.; Brainard, Caroline E.Case HBS-302S36Knowledge and CommunicationDescribe los primeros cuatro años de permanencia de Jack Welch como CEO de las ofertas de General Electric Co. con las formas Welch ha tratado de actividades de estrategia y planificación del cambio de GE y sus intentos de hacer la empresa más empresarial.Starting at €8.20
-
Poles apart on PZU (C)
Gino, Francesca; Dessain, Vincent; Misztal, Karol; Khayyat, MichaelCase HBS-912015-EAfter a decade-long dispute with the Polish State Treasury, in October 2009 the Dutch insurer Eureko agreed to exit PZU in exchange for compensation. Who was the biggest beneficiary of the settlement: Eureko, the Treasury, or PZU itself?Starting at €5.74
-
Veolia: Resourcing the World
Ahuja, Gautam; Khanna, Tarun; Maslauskaite, Kristina; Dessain, VincentCase HBS-717505-EStrategyA global environmental service provider goes through major changes to offer integrated solutions and reach out to new countries.Starting at €8.20
-
Ilva Steel Taranto: Providing and Polluting (C)
Goldberg, Lena G.; Dessain, Vincent; Pesce, Ottavia; Misztal, KarolCase HBS-314059-EStarting at €5.74
-
BASF: Co-Creating Innovation (B)
Rangan, V. Kasturi; Billaud, Emilie; Dessain, VincentCase HBS-517074-EMarketingSupplement to case 517073.Starting at €5.74